Artificial Pancreas Device Systems Market to represent a Significant Expansion at 20.9% CAGR till 2025 – Insulet Corporation, Bigfoot Biomedical, Medtronic, Dexcom, Admetsys, Beta Bionics, Cellnovo

Artificial pancreas device system are the devices that closely copy the glucose regulating function of fit pancreas. The device not only monitors the glucose levels in the body, it also automatically adjusts the distribution of insulin to reduce high blood glucose levels and lowers the incidence of low blood glucose with less or no input from the patient. According to the Food and Drug Administration, the use of an artificial pancreas is associated with better control of blood sugar levels for people with type 1 diabetes compared with standard treatment. The report would be of an interest to various stakeholders operating in the artificial pancreas device systems market. These stakeholders include artificial pancreas product manufacturers, vendors, and distributors, research institutes and government organizations, venture capitalists and other government funding organizations, research and consulting firms, healthcare institutions and others.

The threshold suspended device systems segment held the major market share among the type segment in the artificial pancreas device systems market

According to a new market research study titled ‘Artificial Pancreas Device Systems Market to 2025 - Global Analysis and Forecasts by Type and Geography. The global artificial pancreas device systems market is expected to reach US$ 2,168.1 Mn in 2025 from US$ 481.8 Mn in 2017. The market is estimated to grow with a CAGR of 20.9% from 2018- 2025. The report highlights the trends prevalent in the global artificial pancreas device systems market and the factors driving the market along with those that act as deterrents to its growth.

Get Sample Copy at https://www.theinsightpartners.com/sample/TIPHE100001232

The report segments the global artificial pancreas device systems market as follows:

Global Artificial Pancreas Device Systems Market - By Type
Control to Range
Control to Target
Threshold- Suspended Device Systems

Global Artificial Pancreas Device Systems Market - By Geography

North America
U.S.
Canada
Mexico

Europe
U.K.
Germany
France

Asia Pacific (APAC)
Japan
China
India

Middle East & Africa (MEA)
South Africa
UAE
Saudi Arabia

South & Central America (SCAM)
Brazil

Browse Complete Report at https://www.theinsightpartners.com/reports/artificial-pancreas-device-system-market

Global artificial pancreas device systems market, based on the type was segmented into control to range, control to target and threshold device systems. In 2017, the threshold suspended device systems segment held a largest market share of 71.5% of the artificial pancreas device systems market, by type. The threshold suspended device systems is the largest segment among the type segment in the artificial pancreas devices system market in 2017 and is also anticipated to hold the largest market in the year 2025. However, the control to target segment is the fastest growing segment and is accounted to grow at the CAGR of 21.4% over the forecast years.

The market is likely to witness a rapid growth owing to factors such as growing prevalence of diabetes, developments by major players, and rise in demand for computerized systems for glycemic control. Additionally, the market is also likely to be accelerated by new product launches by market players that are presently in the pipeline. However, availability of alternatives for artificial pancreas device systems and high cost associated with these systems are expected to hinder the market growth in the coming years.

Key market players of Artificial pancreas device systems market are Defymed, TypeZero Technologies, Inc., Insulet Corporation, Bigfoot Biomedical, Inc., Medtronic, Dexcom, Inc., Admetsys, Beta Bionics, Cellnovo, and Tandem Diabetes Care, Inc. among others. The market players are indulged into bringing new products to the market to keep to the pace of the competitive market nature. For instance, in February, 2018, Medtronic received the U.S. Food and Drug Administration (FDA) approval for new arm indication for the Guardian Sensor 3. The latest indication enables patients to wear the sensor on the upper arm, which delivers more flexible and enhanced performance for users, and improved accuracy to be used with the MiniMed 670G system. Additionally, in July, 2016, Tandem Diabetes Care and TypeZero Technologies entered into an agreement for the launch of TypeZero’s artificial pancreas (AP) tech and Tandem’s t:slim Insulin Pump. This agreement is an important step for bringing closed- loop artificial pancreas system to the diabetes community.

Buy this Report now at https://www.theinsightpartners.com/buy/TIPHE100001232

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: [email protected]

Posted by Sameer Joshi on Wednesday January 09 2019, 2:32 AM EST. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0